Article
Immunology
Suzanne Quinn, Natasha Lenart, Victoria Dronzek, Gina M. Scurti, Nasheed M. Hossain, Michael Nishimura
Summary: Immunotherapy is an effective treatment for cancer, but it only works for a small percentage of patients. Adoptive cell transfer (ACT) is a facet of immunotherapy that involves transferring T cells targeting tumor cells to the patient. The main challenges in ACT are improving clinical responses and reducing adverse events. Current research focuses on identifying novel tumor-targeting T cell receptors, improving safety and efficacy, and combining ACT with other immunotherapies.
Article
Oncology
Saskia J. J. Santegoets, Marij J. P. Welters, Deborah S. S. Schrikkema, Manon R. R. Freriks, Hanna Kok, Bianca Weissbrich, Anouk van den Branden, Carsten Linnemann, Ton N. N. Schumacher, Sabina Adhikary, Gavin Bendle, Sjoerd H. H. van der Burg
Summary: Immunotherapies targeting tumor-specific targets focus on expanding and activating T cells against neoantigens or oncogenic viruses, such as the human papilloma virus type 16 (HPV16). In this study, CD8(+) T cell epitopes in HPV16-induced tumors were identified using multimers and a functional screening platform. Specific HLA-peptide combinations dominated the T cell response in patients expressing these HLA alleles. T cell receptors reactive to HLA class I-restricted peptides could be isolated and shown to have tumor reactivity. These tumor-reactive T cell receptors can potentially be used in adoptive cell transfer approaches for treating HPV16-induced cancers.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Biochemistry & Molecular Biology
Xiao-Rong Yang, Can Pi, Yi-Chen Zhang, Zhi-Hong Chen, Xu-Chao Zhang, Dong-Qin Zhu, Ling-Ling Yang, Jiani C. C. Yin, Jia-Yi Deng, Ming-Yi Yang, Wei-Chi Luo, Yi-Long Wu, Qing Zhou
Summary: Mutations in epidermal growth factor receptor and anaplastic lymphoma kinase are common driver events in non-small cell lung cancer, leading to a high frequency of bone metastases. This study assessed the immune cell infiltrates and T cell receptor profiles in driver gene-positive bone metastases of NSCLC. The results showed the co-existence of cytotoxic and suppressor immune cells, as well as higher T cell receptor diversity and similar clonality in driver-positive metastases. Additionally, differential response to immune checkpoint blockade was observed, possibly related to variations in clone amplification, macrophage composition, and natural killer cell activation.
MOLECULAR CARCINOGENESIS
(2023)
Article
Immunology
Shuai Ma, Yixu Ba, Hang Ji, Fang Wang, Jianyang Du, Shaoshan Hu
Summary: This study identified TP53, IDH1, C3, and TCF12 as effective antigens for the development of anti-glioma mRNA vaccines. Additionally, four immune subtypes of glioma were consistently found in the TCGA data, each displaying diverse molecular, cellular, and clinical features.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Hua Zhong, Shuai Liu, Fang Cao, Yi Zhao, Jianguo Zhou, Feng Tang, Zhaohua Peng, Yangsheng Li, Shen Xu, Chunlin Wang, Guohua Yang, Zhi-Qiang Li
Summary: This study identified four potential antigens for anti-glioma mRNA vaccine production and discovered three immune subtypes (IS1-IS3) in glioma patients, showing significant differences in prognosis and immune characteristics. Patients in subtypes IS2 and IS3 demonstrated better outcomes than those in IS1, indicating the potential for tailored mRNA vaccination for applicable glioma recipients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Cell Biology
Cong Liu, Dimitri Papukashvili, Yu Dong, Xingyun Wang, Xing Hu, Nuo Yang, Jie Cai, Fengfei Xie, Nino Rcheulishvili, Peng George Wang
Summary: This study identified potential antigens for effective mRNA vaccine design and built an immune landscape for accurate patient selection for mRNA vaccine therapy in CRC. The study also revealed significant cellular and molecular differences among different immune subtypes.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Engineering, Biomedical
Yue Gao, Zhijun Ouyang, Chao Yang, Cong Song, Chunjuan Jiang, Shaoli Song, Minguiu Shen, Xiangyang Shi
Summary: A novel dendrimer-based nanohybrid platform is developed for dual-mode CT/MR imaging-guided cancer immunotherapy by regulating T cell exhaustion, showing promising potential for overcoming immune escape of cancer cells and improving the efficiency of cancer immunotherapy.
ADVANCED HEALTHCARE MATERIALS
(2021)
Article
Biology
Romain Darrigrand, Alison Pierson, Marine Rouillon, Dolor Renko, Mathilde Boulpicante, David Bouyssie, Emmanuelle Mouton-Barbosa, Julien Marcoux, Camille Garcia, Michael Ghosh, Mouad Alami, Sebastien Apcher
Summary: The study demonstrated that the spliceosome inhibitor IP2 can enhance antigen presentation, activate CD8(+) T cell response, and inhibit tumor growth by modifying the antigen repertoire displayed on MHC-I molecules in cancer cells. Combination of IP2 with a peptide vaccine targeting a specific epitope showed a synergistic antitumor effect.
COMMUNICATIONS BIOLOGY
(2021)
Article
Multidisciplinary Sciences
Jani Huuhtanen, Liang Chen, Emmi Jokinen, Henna Kasanen, Tapio Lonnberg, Anna Kreutzman, Katriina Peltola, Micaela Hernberg, Chunlin Wang, Cassian Yee, Harri Lahdesmaki, Mark M. Davis, Satu Mustjoki
Summary: Analyzing T cell receptor (TCR) repertoire data from melanoma patients and healthy controls, we discovered the significance of antigen-specific T cells in distinguishing patients and predicting metastatic recurrence. These findings provide insights into human disorders.
NATURE COMMUNICATIONS
(2022)
Review
Oncology
Andrea Aran, Laia Garrigos, Giuseppe Curigliano, Javier Cortes, Merce Marti
Summary: The study of TCR repertoire in cancer patients is important for understanding the anti-tumoural response, predicting prognosis, and determining response to immune checkpoint inhibitor therapies. The TCR repertoire is influenced by various factors and can provide valuable insights for modulating immune responses and predicting outcomes.
Article
Computer Science, Theory & Methods
Lang Li, Lvyuan He, Ying Zhu
Summary: This study identified potential tumor antigens, such as SLC7A5, CHPF, CCNE1, and CENPW, for mRNA vaccine development in breast cancer (BRCA). It also found that patients with IS2 tumors are a suitable population for mRNA vaccination. The study provides new insights into mRNA vaccine development, population selection for vaccination, and prognosis prediction.
JOURNAL OF BIG DATA
(2023)
Article
Oncology
Francois Anna, Elodie Bole-Richard, Joel LeMaoult, Marie Escande, Martin Lecomte, Jean-Made Certoux, Philippe Souque, Francine Garnache, Olivier Adotevi, Pierre Langlade-Demoyen, Maria Loustau, Julien Caumartin
Summary: CAR-T cell immunotherapy is a breakthrough in treating hematological malignancies, but the lack of tumor-specific antigens and immunosuppressive tumor microenvironments remain major hurdles. A new study shows that HLA-G, acting as both an immune checkpoint and a tumor-specific antigen, could be a promising target for CAR-T cell therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Immunology
Zhuolun Sun, Changying Jing, Hailun Zhan, Xudong Guo, Ning Suo, Feng Kong, Wen Tao, Chutian Xiao, Daoyuan Hu, Hanbo Wang, Shaobo Jiang
Summary: In this study, potential antigens for mRNA-based vaccines against bladder urothelial carcinoma (BLCA) were identified. Furthermore, two immune clusters were identified, with patients in IC2 potentially benefiting more from vaccination.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Pharmacology & Pharmacy
Wei Shi, Shuang Chen, Fanglian Chi, Qianqian Qiu, Yue Zhong, Xiaojian Bian, Hao Zhang, Junting Xi, Hai Qian
Summary: Elimination of tumors through immune system regulation is a major focus in the field of immune-oncology. Tumor antigen-based cancer vaccines are recognized as promising treatments in immunotherapy, as they can elicit specific and potent anti-tumor immune responses with less toxicity and side effects. However, systematic reviews based on tumor antigens are scarce.
ADVANCED THERAPEUTICS
(2023)
Review
Oncology
Zhangguo Chen, Jessy John, Jing H. Wang
Summary: This study explores the possible reasons for the heterogeneity of immune checkpoint inhibitor (ICI) response in head and neck squamous cell carcinoma (HNSCC). The findings suggest that the response to ICI in HNSCC is associated with genetic, transcriptional, and functional variations in tumor cells, as well as the composition of the immune tumor microenvironment (TME) and the relative abundance of immune subsets. These findings have potential implications for designing personalized immunotherapy strategies.
FRONTIERS IN ONCOLOGY
(2022)
